September 2023 in “bioRxiv (Cold Spring Harbor Laboratory)” The mTurq2-Col4a1 mouse model shows that cells can divide while attached to stable basement membranes during development.
6 citations
,
May 2014 in “Biomarkers and Genomic Medicine” Charnoly bodies could be a marker for cell damage, and certain nutrients and proteins might prevent them, potentially helping with brain diseases and cancer.
March 2026 in “Zenodo (CERN European Organization for Nuclear Research)” The N-K GM Series offers highly selective, eco-friendly antimicrobials free for everyone.
56 citations
,
April 2019 in “The Plant Journal” Cyclic nucleotide-gated channels are crucial for proper root hair growth and calcium balance in plants.
April 2013 in “e-Competitions Bulletin” In 2013, the FTC settled with hair company Bosley over claims it illegally shared business information with a competitor.
October 2024 in “Medicine” Cronkhite-Canada syndrome is rare, has a poor prognosis, and requires early diagnosis and ongoing treatment.
December 2025 in “Cosmetics” The bio-based complex effectively repairs and protects chemically damaged hair.
2 citations
,
August 2022 in “World Journal of Clinical Cases” Albumin and prednisone improved symptoms in a woman with Cronkhite-Canada syndrome, revealing potential genetic causes.
February 2026 in “Regenerative Biomaterials” Strontium and cerium are most effective for tissue repair.
43 citations
,
December 1988 in “International Journal of Bio-Medical Computing”
9 citations
,
March 2022 in “Journal of radiation research” Boron neutron capture therapy for head and neck cancer can cause side effects like mouth sores and skin irritation, which vary depending on where the treatment is aimed.
November 2022 in “The Journal of Urology” Adopting the Mark Cuban Cost Plus Drug Company pricing model could save Medicare about $1.29 billion on urological drugs.
September 2025 in “Cureus” There is no standard treatment for CCCA, and practices vary widely.
April 2020 in “Journal of the Endocrine Society” Hair cortisol measurement can help diagnose and monitor Cushing’s disease.
11 citations
,
January 2022 in “Experimental Dermatology” Severe CCCA may be biologically and clinically different from milder forms.
32 citations
,
September 2013 in “Breast cancer research” A specific gene variant is linked to a higher risk of hair loss from chemotherapy in breast cancer patients.
January 2025 in “Nanoscale” Boron/nitrogen-doped carbon nano-onions improve targeted breast cancer treatment by enhancing drug delivery and reducing side effects.
13 citations
,
January 2010 in “PubMed”
15 citations
,
May 2010 in “International Journal of Cosmetic Science” The cell membrane complex in mammalian hair has three distinct types with different structures and chemical properties.
April 2018 in “Journal of Investigative Dermatology” The new protocol using Cellutome™ and RCM safely assesses wound healing in detail.
March 2026 in “International Journal of Science Strategic Management and Technology” WomenCare helps predict PCOD risk in women to encourage early medical consultation.
April 2024 in “Journal of the American Academy of Dermatology” Diagnosing and treating CCCA requires understanding multiple causes and using various diagnostic tools.
September 2023 in “Journal of the American Academy of Dermatology” BAP1 mutations are rare in pediatric melanocytic tumors and may develop later in life.
2 citations
,
December 2019 in “Bioanalysis” Accurate quantitative bioanalysis using LC-MS/MS is challenging due to matrix effects, but using internal standards and new methods like in-sample calibration could improve results.
June 2023 in “British Journal of Dermatology” The prototype for analyzing skin aging works technically and clinically.
1 citations
,
February 2023 in “Pharmaceutics” Cell proteomic footprinting enhances cancer vaccine quality by ensuring correct antigen composition.
9 citations
,
January 2018 in “Acta Clinica Croatica” Bendamustine, often combined with other drugs, is effective and less toxic for certain blood cancers, but less effective for young, fit patients with CLL.
2 citations
,
July 2007 in “Cancer biology & therapy” Bexxar is highly effective as a first treatment for non-Hodgkin's lymphoma, with most patients alive and many in remission after eight years.
1 citations
,
December 2023 in “Cutis” Toluidine blue helps accurately diagnose and treat certain skin tumors in surgery.
April 2023 in “Journal of Investigative Dermatology” An elderly woman's upper lip lump, thought to be a mucocele, was actually a rare type of lymphoma usually found on legs, treated successfully with chemotherapy and radiation.